Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Closed Solicitation Posted
- Solicitation number
- HT9402-26-Q-9102
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- San Antonio, Texas 78230, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency is soliciting quotes for pharmaceutical agents to be placed on the Department of Defense Uniform Formulary for the Military Health System, with quotes due December 9, 2025, and a pre-quotation teleconference scheduled November 20, 2025.
The solicitation covers six newly approved drugs under review at the February 4–5, 2026 P&T Committee meeting: Jascayd (Pulmonary-1 Agents for Idiopathic Pulmonary Fibrosis), Lynkuet (Gynecological Agents), Palsonify (Endocrine Agents), Rhapsido (Atopy), Tonmya (Skeletal Muscle Relaxants and Tricyclic Antidepressants), and Vyscoxa (Pain Agents, NSAID). The RFQ HT9402-26-Q-9102 and price list templates are attached.
Place of performance is San Antonio, Texas 78230. The procurement NAICS code is 325412, Pharmaceutical Preparation Manufacturing; PSC is 6505, Drugs and Biologicals.
The Defense Health Agency may award two types of agreements based on P&T Committee decisions: Uniform Formulary Blanket Purchase Agreements (UF BPA) for Military Treatment Facilities and TRICARE Mail Order Pharmacy, and Uniform Formulary Additional Discount Program Agreements (UF ADP) for TRICARE retail network pharmacies. Manufacturers must submit quotes for all NDC-11 package sizes with pricing consistent across packages and dispensing venues. Pricing submissions include Federal Ceiling Price, Non-Federal Average Manufacturer Price (non-FAMP), and Wholesale Acquisition Cost (WAC) discount methodologies, along with potential refund percentages. The P&T Committee will evaluate agents based on clinical effectiveness and relative cost effectiveness, with authority to recommend preferential status, tier designation (Uniform Formulary, Tier 2, Tier 3, or Non-Formulary), prior authorization, step therapy, or exclusion from the TRICARE pharmacy benefit program. Manufacturers are not obligated to obtain a Distribution and Pricing Agreement.
Notice text
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: The following February 2026 newly approved drugs will be reviewed:
a. Jascayd - Pulmonary-1 Agents - Idiopathic PF
b. Lynkuet - Gynecological Agents Misc- NA
c. Palsonify - Endocrine Agents Misc - NA
d. Rhapsido - Atopy - NA
e. Tonmya - Skeletal Muscle Relaxants and Comb - TCA
f. Vyscoxa - Pain Agents - NSAID
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9102.
Pre-quotation teleconference is on November 20, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
Files
| File | Type | Posted |
|---|---|---|
| RFQ HT9402-26-Q-9102 NAD.pdf | ||
| Price List - Jascayd - Pulmonary-1- Idiopathic PF.xlsx | XLSX spreadsheet | |
| Price List - Palsonify - Endocrine Agents Misc - NA.xlsx | XLSX spreadsheet | |
| Price List - Vyscoxa - Pain Agents - NSAID.xlsx | XLSX spreadsheet | |
| Price List - Lynkuet - Gynecological Agents Misc- NA.xlsx | XLSX spreadsheet | |
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| Price List - Rhapsido - Atopy - NA.xlsx | XLSX spreadsheet | |
| Price List - Tonmya - SMRs and Comb - TCA.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ NAD.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity